QQQ   413.25 (-2.40%)
AAPL   164.94 (-1.26%)
MSFT   398.78 (-1.36%)
META   479.54 (-4.44%)
GOOGL   153.73 (-1.46%)
AMZN   174.12 (-2.85%)
TSLA   146.72 (-2.14%)
NVDA   760.89 (-10.14%)
AMD   146.70 (-5.40%)
NIO   3.79 (-5.25%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.12 (+0.50%)
MU   106.91 (-4.48%)
GE   147.81 (-3.35%)
CGC   7.94 (+1.40%)
DIS   112.36 (-0.06%)
AMC   3.15 (+7.88%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.92 (+1.18%)
QQQ   413.25 (-2.40%)
AAPL   164.94 (-1.26%)
MSFT   398.78 (-1.36%)
META   479.54 (-4.44%)
GOOGL   153.73 (-1.46%)
AMZN   174.12 (-2.85%)
TSLA   146.72 (-2.14%)
NVDA   760.89 (-10.14%)
AMD   146.70 (-5.40%)
NIO   3.79 (-5.25%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.12 (+0.50%)
MU   106.91 (-4.48%)
GE   147.81 (-3.35%)
CGC   7.94 (+1.40%)
DIS   112.36 (-0.06%)
AMC   3.15 (+7.88%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.92 (+1.18%)
QQQ   413.25 (-2.40%)
AAPL   164.94 (-1.26%)
MSFT   398.78 (-1.36%)
META   479.54 (-4.44%)
GOOGL   153.73 (-1.46%)
AMZN   174.12 (-2.85%)
TSLA   146.72 (-2.14%)
NVDA   760.89 (-10.14%)
AMD   146.70 (-5.40%)
NIO   3.79 (-5.25%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.12 (+0.50%)
MU   106.91 (-4.48%)
GE   147.81 (-3.35%)
CGC   7.94 (+1.40%)
DIS   112.36 (-0.06%)
AMC   3.15 (+7.88%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.92 (+1.18%)
QQQ   413.25 (-2.40%)
AAPL   164.94 (-1.26%)
MSFT   398.78 (-1.36%)
META   479.54 (-4.44%)
GOOGL   153.73 (-1.46%)
AMZN   174.12 (-2.85%)
TSLA   146.72 (-2.14%)
NVDA   760.89 (-10.14%)
AMD   146.70 (-5.40%)
NIO   3.79 (-5.25%)
BABA   69.02 (+0.20%)
T   16.49 (+0.98%)
F   12.12 (+0.50%)
MU   106.91 (-4.48%)
GE   147.81 (-3.35%)
CGC   7.94 (+1.40%)
DIS   112.36 (-0.06%)
AMC   3.15 (+7.88%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.92 (+1.18%)
Free Trial
NASDAQ:TTOO

T2 Biosystems (TTOO) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)
Free TTOO Stock Alerts
$2.94
-0.05 (-1.67%)
(As of 03:42 PM ET)
Compare
Today's Range
$2.92
▼
$3.07
50-Day Range
$2.79
▼
$6.49
52-Week Range
$2.70
▼
$70.00
Volume
31,354 shs
Average Volume
248,990 shs
Market Capitalization
$16.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media
TTOO stock logo

About T2 Biosystems Stock (NASDAQ:TTOO)

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

TTOO Stock Price History

TTOO Stock News Headlines

April 15, 2024 | americanbankingnews.com
T2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest Update
April 13, 2024 | investing.com
T2 Biosystems converts $15M loan to equity, aims for Nasdaq compliance
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
April 12, 2024 | finanznachrichten.de
T2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
April 11, 2024 | globenewswire.com
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
March 28, 2024 | finanznachrichten.de
T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
March 28, 2024 | globenewswire.com
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
March 20, 2024 | finanznachrichten.de
T2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
March 20, 2024 | markets.businessinsider.com
T2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick Facts
March 20, 2024 | globenewswire.com
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
March 19, 2024 | globenewswire.com
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
March 18, 2024 | globenewswire.com
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
March 12, 2024 | investorplace.com
TTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance
March 12, 2024 | finanznachrichten.de
T2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
March 12, 2024 | globenewswire.com
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
February 16, 2024 | money.usnews.com
T2 Biosystems Inc
February 16, 2024 | finance.yahoo.com
T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call Transcript
February 16, 2024 | finanznachrichten.de
T2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
February 16, 2024 | finance.yahoo.com
Q4 2023 T2 Biosystems Inc Earnings Call
February 15, 2024 | finance.yahoo.com
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
February 15, 2024 | finance.yahoo.com
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
February 15, 2024 | finance.yahoo.com
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024 | globenewswire.com
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024 | globenewswire.com
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
February 15, 2024 | globenewswire.com
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
February 14, 2024 | benzinga.com
Earnings Preview For T2 Biosystems
See More Headlines
Receive TTOO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/19/2024
Next Earnings (Estimated)
5/28/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
NASDAQ:TTOO
CUSIP
N/A
CIK
1492674
Web
www.t2biosystems.com
Phone
(781) 761-4646
Fax
781-357-3080
Employees
113
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-50,080,000.00
Net Margins
-696.19%
Pretax Margin
-696.19%
Return on Equity
N/A
Return on Assets
-129.79%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.45
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$7.19 million
Price / Sales
2.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($6.91) per share
Price / Book
-0.43

Miscellaneous

Outstanding Shares
5,510,000
Free Float
5,506,000
Market Cap
$16.47 million
Optionable
Optionable
Beta
0.11
Elon Musk's Next Move Cover
Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

TTOO Stock Analysis - Frequently Asked Questions

How have TTOO shares performed in 2024?

T2 Biosystems' stock was trading at $6.28 on January 1st, 2024. Since then, TTOO shares have decreased by 53.2% and is now trading at $2.94.
View the best growth stocks for 2024 here.

Are investors shorting T2 Biosystems?

T2 Biosystems saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 396,900 shares, an increase of 34.4% from the March 15th total of 295,400 shares. Based on an average daily volume of 255,400 shares, the short-interest ratio is currently 1.6 days. Currently, 11.6% of the shares of the stock are short sold.
View T2 Biosystems' Short Interest.

When is T2 Biosystems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024.
View our TTOO earnings forecast.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) released its quarterly earnings results on Thursday, November, 4th. The medical equipment provider reported ($400.00) earnings per share for the quarter, meeting the consensus estimate of ($400.00). The medical equipment provider had revenue of $7.43 million for the quarter. During the same quarter in the previous year, the firm earned ($400.00) earnings per share.

When did T2 Biosystems' stock split?

T2 Biosystems shares reverse split before market open on Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its fourth quarter 2023 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 million-$1.7 million, compared to the consensus revenue estimate of $2.4 million.

What is John McDonough's approval rating as T2 Biosystems' CEO?

36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

How do I buy shares of T2 Biosystems?

Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TTOO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press